Abstract
With great interest, we read the recent article by Cho et al. (Cho et al. 2015). regarding the high titers of anti-HBs prevent rituximab-related viral reactivation in resolved hepatitis B patient with non-Hodgkin's lymphoma. The authors very clearly determined the predictive factors for rituximab-related HBV reactivation in resolved hepatitis B patients, defined as HBsAg-negative, anti-HBc-positive, and undetectable HBV DNA. This article is protected by copyright. All rights reserved
from #Medicine via ola Kala on Inoreader http://ift.tt/1N9ntnh
via IFTTT
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου
Σημείωση: Μόνο ένα μέλος αυτού του ιστολογίου μπορεί να αναρτήσει σχόλιο.